Avacta Group - Initiation
Avacta has two proprietary drug development platforms, pre|CISION™ and Affimer® and two divisions, Therapeutics and Diagnostics, of which Therapeutics dominates valuation. Avacta is currently shepherding its AVA6000 agent, the first fruit of its pre|CISION™ platform, through Phase 1a clinical trials with highly promising but early stage initial results. While this compound alone could easily be worth £10/share, given the high risk of clearing all clinical trials and the time value of money, we calculate a current value of 18p/share rising to 83p/share should commercialisation commence straight after Phase 2 trials. Avacta hopes to move to Phase 1b testing for AVA6000 later this year and, with £42m in cash at YE22, could be fully funded to Phase 2 trials.Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.